ESR1 and breast carcinoma: It was observed that LIG treatment restored the growth inhibition of TAM on ERα-breast cancer cells, reactivated ERα expression and transcriptional activity, increased the Ace-H3 (lys9/14) enrichment in the ERα promoter, reduced the enrichment of metastasis-associated protein 1 (MTA1) as well as IFN-γ-inducible protein 16 (IFI16) and HDACs on the ERα promoter, and also enhanced the Ace-H3 (lys9/14) enrichment in the ERα promoter.